;
Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Analyst tracks

    Biotech investor, banker and analyst personnel changes

    Ebb & Flow Analyst Tracks Boris Peaker joined Cowen and Co. as a managing director covering biotech. Peaker was a senior research analyst covering biotech at Oppenheimer & Co. Edward Nash joined SunTrust Robinson …

    Published on 7/21/2014
  • Yellen or Yawning?

    Buysiders' long-term outlook unchanged by Yellen's remarks on biotech

    Ebb & Flow Yellen or yawning? Figure: Money Raised in 2014 Table: Earnings on Deck Table: EPS Watch Buysiders don't expect Fed Chairperson Janet Yellen's bearish biotech comments to trigger a long-term downturn …

    Published on 7/21/2014
  • Highlights of weekly biotech stock moves

    Regulatory, clinical and other milestones

    EBB & FLOW REGULATORY MILESTONES Basilea Pharmaceutica AG (SIX:BSLN) was up CHF0.35 to CHF97.90 last week after submitting an MAA to EMA for isavuconazole to treat invasive aspergillosis and invasive mucormycosis (…

    Published on 7/21/2014
  • UCB's better housekeeping

    Why UCB tapped European Investment Bank to fund six pharma programs

    Ebb & Flow UCB'S Better Housekeeping At first blush it seems odd that UCB Group (Euronext:UCB) would source up to €75 million from the European Investment Bank (EIB) to help fund its pipeline programs - the company …

    Published on 7/21/2014
  • A little debt'll do 'ya

    Why ZS Pharma added modest debt deal on top of big IPO

    Ebb & Flow A little debt'll do 'ya ZS Pharma Inc. (NASDAQ:ZSPH) wasted no time topping off its $123 million IPO with a $20 million debt facility through MidCap Financial to support development of hyperkalemia …

    Published on 7/21/2014
  • Figure: Money Raised in 2014

    Yellen or Yawning? Money Raised in 2014 Last week, the biotech industry raised $368 million, bringing to $33.1 billion the total raised year-to-date. In 2013, a total of $37 billion was raised, including $14.4 …

    Published on 7/21/2014
  • Table: Earnings on Deck

    Yellen or Yawning? Earnings on Deck At least 16 biotechs and pharmas are slated to report earnings this week. Two large-cap biotechs - Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Gilead Sciences Inc. (NASDAQ:GILD…

    Published on 7/21/2014
  • Table: EPS Watch

    Yellen or Yawning? EPS Watch At least five biotechs and pharmas reported earnings last week. Shire plc (LSE:SHP; NASDAQ:SHPG) reported 2Q14 EPS and revenues that beat the Street's estimates and also announced it …

    Published on 7/21/2014
  • Analyst tracks

    Biotech investor, banker and analyst personnel changes

    Analyst tracks Salveen Richter joined SunTrust Robinson Humphrey as a senior biotech analyst. Richter was a managing director, biotechnology equity research, at Canaccord. Banker tracks Toshiyuki Mori joined Whiz …

    Published on 7/14/2014
  • 3Q14 Financial Markets Preview: Discerning optimism

    Biotech investors: bottom hit but will be selective on IPOs, small caps in 3Q14

    Buysiders hope correction has provided a floor for a biotech recovery, with investors being selective on IPOs and small caps in 2H14.

    Published on 7/14/2014
  • 3Q14 Financial Markets Preview: Summer lull

    Biotech investors expect quiet 3Q14, position portfolios for larger events in 4Q

    With some notable exceptions, investors anticipate a quiet 3Q14 in terms of milestones and are positioning their portfolios for larger events later in the year.

    Published on 7/14/2014
  • Figure: Healthcare/biotech fund flows

    Discerning optimism Healthcare/biotech fund flows About $6.8 billion exited healthcare/biotech funds last quarter. But net funds are still up $5.3 billion for the year, thanks to inflows of $12.1 billion in 1Q14. …

    Published on 7/14/2014
  • Table: Follow-on performance

    Discerning optimism Follow-on performance Biotechs have raised $7.2 billion via 95 follow-ons in 2014, averaging $75.8 million per deal. This compares with $6.5 billion raised in 65 deals in 1H13, an average of $100…

    Published on 7/14/2014
  • Table: IPO performance

    Discerning optimism IPO performance Fifty-nine companies raised $3.9 billion via IPOs in 1H14, compared to 26 that raised $1.5 billion in 1H13. The 1H14 group is up a median of 6% from their initial valuations, with…

    Published on 7/14/2014
  • Table: IPO queue

    Discerning optimism IPO queue A rush of 30 IPO filings since the start of 2Q14 has brought the queue to at least 41. Additionally, in 1Q14, Chinese genomics company BGI Inc. has said it is "working on" an IPO. …

    Published on 7/14/2014
  • Figure: Money Raised in 2014

    Cidara's antimicrobial reunion Money Raised in 2014 Last week, the biotech industry raised $883 million, bringing to $32.7 billion the total raised year-to-date. In 2013, a total of $37.1 billion was raised, …

    Published on 7/14/2014
  • Invoking Sophia

    Invoke providing more than cash to scale Sophia's whole genome sequence analysis

    Invoking Sophia Sophia Genetics S.A. expects to tap into multiple assets from Invoke Capital, the lead investor in the bioinformatics company's $13.8 million series B round. In addition to the cash, Sophia will work …

    Published on 7/14/2014
  • Figure: London vs. Europe

    Large and in charge London vs. Europe The BioCentury Europe index gained 13% in 2Q14, while the BioCentury London index gained 8%. Twelve of 19 continental European biotechs in the market cap-weighted European index…

    Published on 7/14/2014
  • Figure: Price-to-earnings: BT vs RX

    Large and in charge Price-to-earnings: BT vs RX The gap between P/Es for biotech and big pharma contracted last quarter, with biotech's multiple closing at 1.4x that of big pharma. The last time the gap was that …

    Published on 7/14/2014
  • Figure: Results by market cap

    Large and in charge Results by market cap Only one market cap segment - biotechs valued above $5 billion - posted a gain last quarter. That group was up a median of 4%, led by a 59% gain by Shire plc (LSE:SHP; …

    Published on 7/14/2014
  • Table: 2Q approvals and 2Q setbacks

    Large and in charge 2Q approvals Selected second quarter approvals. Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) FDA grants full approval to Soliris eculizumab to treat atypical hemolytic uremic …

    Published on 7/14/2014
  • Table: Index performance

    Large and in charge Index performance The BioCentury 100 index rose only 2% in 2Q14, while the NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices both gained more than 7%. The discrepancy is …

    Published on 7/14/2014
  • Table: Restructuring watch

    Large and in charge Restructuring watch Biotech employee reductions continued at record low levels in 2Q14, when at least four companies reduced their workforces compared to at least 13 in the same period last year.…

    Published on 7/14/2014
  • Highlights of weekly biotech stock moves

    Regulatory, clinical and other milestones

    Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) was down $0.96 to $10.54 last week after partner Gruenenthal Group submitted an MAA to EMA for Zalviso to treat moderate to severe acute pain. The …

    Published on 7/14/2014
  • Cidara's antimicrobial reunion

    Seasoned antiinfectives team at Cidara aiming to disrupt antifungal market

    Ebb & Flow Cidara's antimicrobial reunion Figure: Money Raised in 2014 Investors in Cidara Therapeutics Inc.'s $32 million series A round are hoping for a repeat performance by a management team with a track record…

    Published on 7/14/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993